Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis
| Autor: | Petkau, AJ, White, RA, Ebers, GC, Reder, AT, Sibley, WA, Lublin, FD, Paty, DW, Duquette, P, Girard, M, Despault, L, DuBois, R, Knobler, RL, Kelley, L, Francis, GS, Lapierre, Y, Antel, J, Freedman, M, Hum, S, Greenstein, JI, Mishra, B, Muldoon, J, Whitaker, JN, Evans, BK, Layton, B, Laguna, J, Krikawa, J, Oger, JJ, Kastrukoff, LF, Moore, GRW, Hashimoto, SA, Morrison, W, Nelson, J, Goodin, DS, Massa, SM, Gutteridge, E, Arnason, BGW, Noronha, A, Martia, R, Rice, GPA, Lesaux, J, Johnson, KP, Panitch, HS, Bever, CT, Conway, K, Wallenberg, JC, Bedell, L, van den Noort, S, Weinshenker, B, Weiss, W, Reingold, S, Pachner, A, Taylor, W |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2004 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent Exacerbation Neopterin Gastroenterology Antibodies Central nervous system disease Disability Evaluation 03 medical and health sciences Multiple Sclerosis Relapsing-Remitting 0302 clinical medicine Adjuvants Immunologic Internal medicine Secondary Prevention medicine Humans Longitudinal Studies 030212 general & internal medicine Neutralizing antibody Expanded Disability Status Scale biology business.industry Multiple sclerosis Interferon beta-1b Interferon-beta Middle Aged medicine.disease Confidence interval Titer Treatment Outcome Neurology Immunology biology.protein Female Neurology (clinical) business 030217 neurology & neurosurgery |
| Zdroj: | Multiple Sclerosis. 10(2) |
| ISSN: | 1352-4585 |
| Popis: | We have analysed dataon exacerbation rates, Expanded Disability Status Scale (EDSS) scores, and lesion burdens using the results of two neutralizing antibody (NAB) assays (CPE and MxA) from the pivotal relapsing i/remitting multiple sclerosis (MS) trial of interferon beta-1b (IFNB) with a longitudinal approach, where the influence of NABs in individual patients is assessed by comparing responses during NABpositive and NAB-negative periods. There are apparent influences on exacerbation rate related to dose of IFNB, titer level, and duration of positivity. With the MxA assay, exacerbation rates after switching to NAB-positive status are estimated to be 28% higher [95% confidence interval (CI): ( o/15%, 92%)] and o/2% higher [95% CI: ( o/21%, 21%)] on the low- and high-dose IFNB arms, respectively. When compared with all NAB-negative periods, exacerbation rates during NAB-positive periods are estimated to be 29% higher [95% CI: (0%, 67%)] and 18% higher [95% CI: (0%, 40%)] on the low- and high-dose IFNB arms, respectively. When NAB-positive patients again become NAB-negative, no evidence of increased exacerbation rates could then be demonstrated. More detailed exploratory analyses indicate that the effects are most evident in the approximately 20% of patients developing high titers. In these patients, the influence of NABs may be self-limited, as titers often diminish or NABs become undetectable with time. Multiple Sclerosis (2004) 10, 126i/138 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|